Finch, Takeda to Jointly Develop Microbiome Therapeutic for Ulcerative Colitis

Finch, Takeda to Jointly Develop Microbiome Therapeutic for Ulcerative Colitis
Japan's Takeda Pharmaceutical and Boston-based Finch Therapeutics will jointly develop the drug FIN-524 to treat ulcerative colitis, a form of inflammatory bowel disease (IBD). FIN-524 is Finch's first microbiotic product candidate. The company says its live biotherapeutic product consists of cultured bacteria strains, and is based on a rationally designed, synthetic ecology of microbes. FIN-524 is now in the pre-clinical research stage. The new collaboration melds Finch's proprietary discovery platform with Takeda's muscle in gastrointestinal (GI) drug development to speed advancement of a new class of microbial therapy for IBD. In the 1990s, Tak
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *